Thursday, March 03, 2016 9:17:43 AM
A market research report titled "Endometrial Cancer - Pipeline Review, H2 2015" provides an overview of the Endometrial Cancer's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Company Profiles discussed in this report includes Ability Pharma, SL, Acceleron Pharma, Inc., Advenchen Laboratories, LLC, Aeterna Zentaris Inc., Arno Therapeutics, Inc., ArQule, Inc., AstraZeneca Plc, AVEO Pharmaceuticals, Inc., BeiGene(Beijing) Co.,Ltd, Boehringer Ingelheim GmbH, Cellceutix Corporation, Critical Outcome Technologies Inc., Eisai Co., Ltd., Eli Lilly and Company, Esperance Pharmaceuticals, Inc., Exelixis, Inc., Galena Biopharma, Inc., Genmab A/S, GlaxoSmithKline Plc, Gradalis Inc., ImmunoGen, Inc., Incyte Corporation, Karyopharm Therapeutics, Inc., Medivation, Inc., Merck & Co., Inc., Merck KGaA, Millennium Pharmaceuticals, Inc., Novartis AG, OncoHoldings, Inc., Oncothyreon Inc., Otsuka Holdings Co., Ltd., Pharma Mar, S.A., Pharmsynthez, Puma Biotechnology, Inc., Sanofi, Scancell Holdings Plc and Shenogen Pharma Group Ltd. Complete report on H2 2015 pipeline review of Endometrial Cancer with 57 market data tables and 16 figures, spread across 280 pages is available at http://www.reportsnreports.com/reports/453485-endometrial-cancer-pipeline-review-h2-2015.html .
Drugs Profiles discussed in this report includes Pb-TCMC-Trastuzumab, ABTL-0812, AEZS-125, AL-3818, ARQ-092, AV-203, AZD-2014, AZD-5363, BGB-283, buparlisib hydrochloride, cabozantinib s-malate, cancer vaccine, Cell Therapy for Ovarian and Endometrial Cancer, Cell Therapy to Target HER-2 for Oncology, CLR-457, COTI-2, cridanimod, dalantercept, EP-200, epacadostat, everolimus, GALE-301, GSK-2636771, HO-3867, HuMax-TF-ADC, INCB-54828, KM-3174, lenvatinib, lurbinectedin, LY-3023414, mirvetuximab soravtansine, MK-2206, Modi-1, Monoclonal Antibody to Inhibit L1CAM for Ovarian and Endometrial Cancer, neratinib, nintedanib, onapristone ER, ONCO-101, ONT-10, OPB-111001, Peptides to Inhibit GnRH II Receptor for Oncology, pimasertib hydrochloride + voxtalisib, sapanisertib, SAR-408701, selinexor, Small Molecules to Inhibit Skp2 for Endometrial Cancer and Melanoma, SNG-1153, SP-2509, talazoparib, trametinib dimethyl sulfoxide + uprosertib, X-480 and zoptarelin doxorubicin.
Order a Purchase copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=453485 .
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM